Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2019-11-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well daunorubicin hydrochloride, cytarabine, and nilotinib
work in treating patients newly diagnosed with acute myeloid leukemia. Drugs used in
chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to
stop the growth of cancer cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Nilotinib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Giving daunorubicin hydrochloride with cytarabine
and nilotinib may kill more cancer cells.